Tuvigin 0.5 mg Capsule
PDF Leaflet Revision Date: 05 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Disease modifying therapy for relapsing multiple sclerosis.
Dosage (summary)
0.5 mg orally once daily, with or without food.
Onset of Action / Duration
Onset: 6 hours, Duration: 1 month for heart rate normalization.
Special Populations
- Elderly population
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic in animals.
Key Drug Interactions
- Anti-dysrhythmic medicines (Class Ia and III)
- Beta blockers
- Calcium channel blockers
Contraindications
- Hypersensitivity to fingolimod
- Pregnancy and lactation
- Recent myocardial infarction or stroke
- Severe cardiac arrhythmias
Common side effects
- Headache
- Influenza
- Diarrhoea
- Sinusitis
- Back pain
Counselling Points
- Monitor for signs of infection.
- Report any visual disturbances.
- Use effective contraception during treatment.
Serious warnings
- Risk of bradydysrhythmia
- Increased risk of infections
- Progressive multifocal leukoencephalopathy (PML)
Important Disclaimer
The Tuvigin 0.5 mg Capsule professional information leaflet below is the property of Sandoz Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
